June 22, 2019 : Issue #995

TOP STORIES — Diabetes News and Research: ADA 2019

Oral Semaglutide vs Subcutaneous GLP-1RAs

The Incidence of Type 2 Diabetes in Patients Receiving Vitamin D Supplementation

Delayed Onset of Type 2 Diabetes Through Early Lifestyle Interventions

For many years the Holy Grail of diabetes therapy has been oral insulin. The thought process has been: if patient did not have to inject, they would be happy to use insulin multiple times a day. While we don’t seem that close to oral insulin, we do have an opportunity to convert a very popular class of drugs from injectable to oral.

Now that Novo Nordisk have submitted an application to the FDA for oral semaglutide, we will see if patients really prefer oral over injectable. One thing we know for sure: it is a lot harder to meet the requirements for taking the oral than injecting.

This week our University of South Florida PharmD Candidate Adam Chalela has an article looking at the one thing that might get patients to jump through the oral hoops to use the medication. Click here to learn more.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

New research findings on oral semaglutide vs subcutaneous liraglutide.

The role of 25-hydroxyvitamin D in the progression of type 2 diabetes continues to be explored after a recent study observes diabetes incidence in high risk patients receiving vitamin supplementation.

Thirty years of follow-up data show significant reductions in morbidities and mortality in patients with prediabetes who initiate lifestyle modifications.

The findings from data for 35,819 mother-infant pairs, presented at the American Diabetes Association Annual meeting and published in the Journal of the American Medical Association, found that children whose mothers had A1C levels greater than 6.5% during early pregnancy were almost two times as likely to be diagnosed with autism in the first 4 years of life as those whose mothers had A1C levels below 5.7%.  Epidemiologic data suggest that maternal diabetes influences the risk for autism in offspring. The prevalence of autism has steadily risen in the U.S., currently affecting 1 in 59 children. Maternal diabetes, if not well treated, means hyperglycemia in utero, which increases uterine inflammation, oxidative stress and hypoxia and may alter gene expression. This can disrupt fetal brain development, increasing the risk for neural behavior disorders, such as autism.  Journal of the American Medical Association

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Adam Chalela, B.S., Doctor of Pharmacy Candidate, Class of 2020, USF College of Pharmacy

Maya Rudolph, PharmD Candidate, Florida A&M University College of Pharmacy & Pharmaceutical Sciences

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com